Combined Sabal and Urtica Extracts (WS® 1541) Exert Anti-proliferative and Anti-inflammatory Effects in a Mouse Model of Benign Prostate Hyperplasia
Open Access
- 29 March 2019
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 10, 311
Abstract
WS® 1541 is a phytopharmaceutical drug combination containing a lipophilic extract from fruits of Sabal serrulata (WS® 1473) and an aqueous ethanolic extract from roots of Urtica dioica (WS® 1031). It is approved in several countries worldwide for the treatment of lower urinary tract syndrome (LUTS) linked to benign prostate hyperplasia (BPH). Clinical studies have demonstrated the efficacy of this unique combination in the treatment of BPH-related LUTS. However, its mechanisms of action in vivo remain partly uncharacterized. The aim of this study was to take advantage of a validated mouse model of BPH to better characterize its growth-inhibitory and anti-inflammatory properties. We used the probasin–prolactin (Pb-PRL) transgenic mouse model in which prostate-specific overexpression of PRL results in several features of the human disease including tissue hypertrophy, epithelial hyperplasia, increased stromal cellularity, inflammation, and LUTS. Six-month-old heterozygous Pb-PRL male mice were randomly distributed to five groups (11–12 animals/group) orally treated for 28 consecutive days with WS® 1541 (300, 600, or 900 mg/kg/day), the 5α-reductase inhibitor finasteride used as reference (5 mg/kg/day) or vehicle (olive oil 5 ml/kg/day). Administration of WS® 1541 was well tolerated and caused a dose-dependent reduction of prostate weight (vs. vehicle) that was statistically significant at the two highest doses. This effect was accompanied by a reduction in prostate cell proliferation as assessed by lower Ki-67 expression (qPCR and immunohistochemistry). In contrast, finasteride had no or only a mild effect on these parameters. The growth-inhibitory activity of WS® 1541 was accompanied by a strong anti-inflammatory effect as evidenced by the reduced infiltration of cells expressing the leukocyte common antigen CD45. In sharp contrast, finasteride significantly increased the prostate inflammatory status according to this readout. Molecular profiling (qPCR) of 23 selected pro-inflammatory genes confirmed the strong anti-inflammatory potency of WS® 1541 compared to finasteride. Since treatment of WS® 1541 did not interfere with transgene expression and activity in the prostate of Pb-PRL mice, the effects observed in this study are entirely attributable to the intrinsic pharmacological action of the drug combination.Keywords
Funding Information
- Institut National de la Santé et de la Recherche Médicale
- Université Paris Descartes
This publication has 80 references indexed in Scilit:
- EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic ObstructionEuropean Urology, 2013
- Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancerJournal of Translational Medicine, 2011
- Serenoa repens extract in the treatment of benign prostatic hyperplasiaTherapeutic Advances in Urology, 2011
- Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumorsProceedings of the National Academy of Sciences, 2010
- Inflammation in benign prostatic hyperplasia: A 282 patients' immunohistochemical analysisThe Prostate, 2009
- The Relationship between Prostate Inflammation and Lower Urinary Tract Symptoms: Examination of Baseline Data from the REDUCE TrialEuropean Urology, 2008
- The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophyCytokine, 2008
- Evaluation of Prostatitis in Autopsied Prostates—Is Chronic Inflammation More Associated With Benign Prostatic Hyperplasia or Cancer?Journal of Urology, 2008
- Chronic inflammation in benign prostatic hyperplasia: Implications for therapyMedical Hypotheses, 2008
- Interleukin-8 Is a Paracrine Inducer of Fibroblast Growth Factor 2, a Stromal and Epithelial Growth Factor in Benign Prostatic HyperplasiaThe American Journal of Pathology, 2001